All images kindly provided by Yuan Chang,Columbia University.
LANA1 (ORF73) expression in a KS lesion. LANA1 has a punctate nuclear localization pattern.
LANA2 (ORFK10.5) expression in BCBL1 tissue culture cells. The nuclear localization pattern is similar to that of LANA1 but it does not perfectly colocalize with LANA1.
Comparison of LANA1 and LANA2 expression in Kaposi's sarcoma (KS), Castleman's disease (CD) and primary effusion lymphoma (PEL) tissues. Note that LANA1 is expressed in all KSHV-infected tissues in ethanol and allowed to recrystallize through evaporation.
vIRF-1 (ORFK9) expression in BCBL1 tissue culture cells. vIRF-1 shuttles between the cytoplasm and the nucleus as shown in these two cells. Although vIRF-1 is readily seen in PEL tissue culture cell lines,it is rarely expressed in PEL tumors. It is expressed in Castleman's disease tumors.
vIL-6 (ORFK2) expression in the mantle zone of a germinal center in a Castleman's disease (CD) lymph node.vIL-6 is generally not expressed in KS lesions but it is found in both PEL and CD tumors.
Expression of PF-8 (ORF 59) in Castleman's disease germinal center. PF-8 is expressed during lytic KSHV replication and is rarely seen in PEL or KS tumors but is commonly found in CD tumors.
1. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma,primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156:743-9.
2. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001; 156:743-9.
Operated by the University of California for the National Nuclear Security Administration,
of the US Department of Energy. Copyright © 2001 UC | Disclaimer/Privacy